Association between clinical measures and florbetapir F18 PET neuroimaging in mild or moderate alzheimer's disease dementia

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 26, Issue 3, 2014, Pages 214-220

  Witte, Michael M ^a   Trzepacz, Paula ^a,b   Case, Michael ^a   Yu, Peng ^a   Hochstetler, Helen ^a   Quinlivan, Mitchell ^c   Sundell, Karen ^d   Henley, David ^b,d  

^a Lilly USA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Eli Lilly Australia   (Australia)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; FLORBETAPIR F 18; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE DEMENTIA; AMYLOID PLAQUE; ARTICLE; ASSOCIATION; CLINICAL FEATURE; COGNITION; CROSS-SECTIONAL STUDY; DEMENTIA; DIAGNOSTIC ERROR; DISEASE SEVERITY; EXPERIMENTAL THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ANALYSIS OF VARIANCE; BRAIN; DIAGNOSTIC USE; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANILINE COMPOUNDS; BRAIN; CROSS-SECTIONAL STUDIES; ETHYLENE GLYCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES;

EID: 84905699189     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/appi.neuropsych.12120402     Document Type: Article

References (28)

1. Mayeux R, Saunders AM, Shea S, et al; Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998; 338:506-511
2. Beach TG, Monsell SE, Phillips LE, et al: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012; 71:266-273
3. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
4. McKhann GM, Knopman DS, Chertkow H, et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:263-269
5. Jack CR Jr, Albert MS, Knopman DS, et al: Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:257-262
6. Clark CM, Schneider JA, Bedell BJ, et al; AV45-A07 Study Group: Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305:275-283
7. Clark CM, Pontecorvo MJ, Beach TG, et al; AV-45-A16 Study Group: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012; 11:669-678
8. Landau SM, Breault C, Joshi AD, et al; Alzheimer's Disease Neuroimaging Initiative: Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013; 54:70-77
9. Carlson C, Estergard W, Oh J, et al: Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 2011; 7:396-401
10. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
11. Mohs RC, Knopman D, Petersen RC, et al: Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl 2):S13-S21
12. Galasko D, Bennett D, Sano M, et al: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl 2):S33-S39
13. Galasko D, Kershaw PR, Schneider L, et al: Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. J Am Geriatr Soc 2004; 52:1070-1076
14. Berg L, Miller JP, Baty J, et al: Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol 1992; 31:242-249
15. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414
16. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state. " A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
17. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314
18. Aalten P, Verhey FR, Boziki M, et al: Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord 2007; 24:457-463
19. Aalten P, Verhey FR, Boziki M, et al: Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord 2008; 25:1-8
20. Dennehy EB, Kahle-Wrobleski K, Sarsour K, et al: Derivation of a brief measure of agitation and aggression in Alzheimer's disease. Int J Geriatr Psychiatry 2013; 28:182-189
21. Trzepacz PT, Saykin A, Bhamditipati P, et al: Subscale validation of the neuropsychiatric inventory questionnaire: Comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts. Am J Geriatr Psychiatry 2013; 21:607-622
22. Sheikh J, Yesavage J: Geriatric Depression Scale (GDS): recent evidence and development of the shorter version. Clin Gerontol 1986; 5:165-173
23. Choi SR, Golding G, Zhuang Z, et al: Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009; 50:1887-1894
24. Rosenberg PB, Wong DF, Edell SL, et al: Cognition and amyloid load in alzheimer disease imaged with florbetapir F 18 (AV-45) positron emission tomography. Am J Geriatr Psychiatry 2013; 2:272-278
25. Landau SM, Mintun MA, Joshi AD, et al; Alzheimer's Disease Neuroimaging Initiative: Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72:578-586
26. Sperling R, Salloway S, Raskind M, et al: Bapineuzumab phase 3 trials in mild to moderate Alzheimer's disease dementia in apolipoprotein E e4 carriers (study 302) and non-carriers (study 301) 2012; http://www.ctad.fr/07-download/Congres2012/PressRelease/ Final-Sperling-CTAD-Presentation-10-29-12.pdf; accessed Feb 11, 2013
27. Johnson KA, Sperling RA, Gidicsin CM, et al: Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013; 9(Suppl 5):S72-S83
28. Fleisher AS, Chen K, Liu X, et al: Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011; 68:1404-1411